Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas

Pathology International
Masato NakayamaMichio Shimizu

Abstract

Gonadotropin-releasing hormone agonist (GnRH-a) therapy is frequently applied to reduce the volume of uterine leiomyomas (UL). In addition, the possible relationship between mast cells (MC) within UL and the development of UL has been suggested, but the role of MC in UL remains to be determined. UL with or without GnRH-a therapy in 121 premenopausal patients were reviewed. The number of MC was evaluated between the two groups, immunohistochemistry was done for insulin-like growth factor-I (IGF-I), and the association between the IGF-I immunoreactivity in UL and the GnRH-a therapy was analyzed. The number of MC significantly increased in UL in GnRH-a therapy, while IGF-I immunoreactivity was significantly reduced in smooth muscle cells of these UL. Furthermore, IGF-I immunoreactivity in MC was inversely correlated with the size reduction rate of UL in GnRH-a therapy. Although GnRH-a therapy is considered to reduce the size of UL transiently, the regression of UL was in part hampered by the increased IGF-I secretion from the increased MC after GnRH-a therapy. Therefore, the more the IGF-I secretion from MC in UL increases, the less effective the GnRH-a therapy is on the size reduction of UL. Thus, the present study may provide an...Continue Reading

References

Feb 1, 1992·American Journal of Obstetrics and Gynecology·G D Adamson
Jan 1, 1991·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·J CrowP Helliwell
Nov 1, 1987·American Journal of Obstetrics and Gynecology·S G AwadallaM H Kim
Oct 1, 1981·Fertility and Sterility·V C Buttram, R C Reiter
Jun 1, 1995·American Journal of Obstetrics and Gynecology·E Y StrawnC L Bethea
Mar 1, 1995·Diseases of the Colon and Rectum·J LachterM Munichor
Apr 1, 1997·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·R I DemopoulosE C Vamvakas
Oct 24, 1998·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·A OriiS Fujii
Aug 15, 2000·Baillière's Best Practice & Research. Clinical Obstetrics & Gynaecology·R A Nowak
Feb 24, 2001·Lancet·E A Stewart
Apr 19, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Seong H ChoChad K Oh
Nov 1, 1958·Cancer·E F LASCANO
Feb 1, 1965·American Journal of Obstetrics and Gynecology·J E FOX, M R ABELL
Dec 1, 1964·British Journal of Cancer·C BARONI
Feb 25, 2005·American Journal of Reproductive Immunology : AJRI·Masao SugamataIchiro Uchiide
May 1, 2007·American Journal of Obstetrics and Gynecology·Domenico RibattiGastone G Nussdorfer

❮ Previous
Next ❯

Citations

Jul 17, 2015·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·Shakti Bedanta Mishra, Afzal Azim
Jul 16, 2009·Current Opinion in Obstetrics & Gynecology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.